Many are anxiously awaiting results of clinical trials testing NAD+ boosting vitamin supplement Nicotinamide Riboside “NR” (FAQs) (Anecdotes). During yesterday’s earnings call, Niagen Bioscience CEO Rob Fried provided the following update:
Category: Ataxia
From yesterday’s Chromadex (sellers of Nicotinamide Riboside “NR” (FAQs) (Reviews)) earnings call:
In September, scientists reported promising results from a clinical study treating patients suffering from Ataxia Telangiectasia (AT) with NAD boosting vitamin supplement Nicotinamide Riboside “NR” (FAQs) (Reviews). For those unfamiliar, according to the Cleveland Clinic, “Ataxia is the term for a group of neurological diseases (diseases related to the nervous system) that affect movement and coordination”. Last week, the folks at NR seller Chromadex discussed the clinical findings during their latest earnings call: